Emerging Pipeline Medications Beyond Ozempic, Wegovy, and Mounjaro
Over the past decade, GLP-1 receptor agonists such as Ozempic, Wegovy, Mounjaro, Zepbound, and Rybelsus have transformed the treatment of type 2 diabetes and obesity. However, pharmaceutical companies are already developing a new generation of metabolic drugs designed to go beyond the capabilities of current GLP-1 medications.
These experimental treatments are sometimes referred to as “next-generation GLP-1 drugs” because they either enhance the GLP-1 mechanism or combine it with additional hormonal pathways to produce stronger metabolic effects.
More than 80 obesity drugs are currently in development, many of them targeting GLP-1 pathways or related metabolic hormones.
This article explains the most promising experimental and new drugs currently in development or recently placed into the market, how they differ from existing treatments, and why they are attracting so much attention.
Why Pharmaceutical Companies Are Developing Next-Generation GLP-1 Drugs
Current GLP-1 medications already produce impressive results, including significant weight loss and improved blood sugar control. However, they also have limitations.
Researchers are attempting to improve several aspects of these drugs:
Goals of the Next Generation
- Greater weight-loss efficacy
- Fewer gastrointestinal side effects
- Oral medications instead of injections
- Longer dosing intervals
- Improved metabolic control
- Better cardiovascular and liver outcomes
Some experimental drugs may also target multiple hormones simultaneously, which could potentially produce greater metabolic effects than current treatments.
1. Retatrutide (Triple-Hormone “Tri-Agonist”)
One of the most discussed next-generation drugs is retatrutide, currently being developed by Eli Lilly.
Mechanism
Retatrutide activates three different metabolic receptors:
- GLP-1
- GIP
- Glucagon
Because it targets three hormone pathways simultaneously, it is often described as a “triple agonist.”
Early Clinical Results
In clinical trials, retatrutide has produced up to about 24% body-weight reduction, approaching results seen with bariatric surgery.
Why It’s Important
Retatrutide is considered by many researchers to represent the next frontier of obesity pharmacotherapy, combining multiple metabolic signals to achieve powerful effects.
If approved, it could become one of the most effective weight-loss medications ever developed.
2. CagriSema (Semaglutide + Cagrilintide Combination)
Another major experimental therapy is CagriSema, developed by Novo Nordisk.
Mechanism
CagriSema combines two hormones:
- Semaglutide (GLP-1)
- Cagrilintide (an amylin analogue)
Amylin is a hormone that helps regulate appetite and slows gastric emptying.
Expected Benefits
By combining GLP-1 with amylin signaling, CagriSema aims to:
- enhance appetite suppression
- increase satiety
- improve metabolic signaling
Clinical trials have shown weight loss around 20% or more, though results have varied between studies.
3. Orforglipron (Foundayo)
Orforglipron, an oral GLP-1 drug from Eli Lilly.
Orforglipron (brand name Foundayo) was approved by the FDA on April 1, 2026. It is a daily oral, non-peptide GLP-1 receptor agonist manufactured by Eli Lilly and Company. Foundayo is a “molecular entity” pill developed by Eli Lilly and marketed using “Foundayo” as a brand name. It is intended for use as a tool to help with chronic weight management and type 2 diabetes. Foundayo operates by stimulating secretion of insulin and lowering appetite without restricting food/water intake. It is extremely useful for loss of weight (up to 11% in 71 weeks). It was greenlighted for 18+ year old patients who are overweight or fat with related medical problems (e.g., hypertension, type 2 diabetes) Usual side effects are gastrointestinal such as diarrhea, nausea, vomiting or constipation.
Why It’s Different
Unlike current GLP-1 drugs, which are peptides requiring injection, orforglipron is a small-molecule oral medication.
This means it could potentially:
- be manufactured at large scale
- eliminate the need for injections
- simplify dosing
Potential Impact
Orforglipron could significantly expand the GLP-1 market by making treatment more accessible and easier to take.
4. Amycretin
Amycretin is a therapy under developed by Novo Nordisk.
Mechanism
Amycretin targets two hormonal pathways:
- GLP-1
- Amylin
This dual action may enhance both appetite suppression and metabolic regulation.
Early Trial Results
Early studies showed substantial weight loss:
- up to 22% body-weight reduction with injections
- about 13% weight loss with oral forms in early trials.
Because it may be available as both an injection and a pill, amycretin has drawn significant attention.
5. Survodutide (GLP-1 + Glucagon Dual Agonist)
Survodutide, developed by Boehringer Ingelheim, is another drug currently in advanced clinical trials.
Mechanism
Survodutide activates two receptors:
- GLP-1
- Glucagon
This combination may increase energy expenditure while suppressing appetite.
Clinical trial data suggest potential weight loss approaching 19%, placing it among the more powerful investigational therapies.
6. VK2735 (Dual GLP-1 / GIP Agonist)
VK2735, developed by Viking Therapeutics, is another drug generating significant interest.
Key Features
- dual GLP-1 / GIP receptor activation
- available as both injectable and oral formulations
- early trials have shown promising weight-loss results
In early studies, some patients lost around 6–7% body weight within only four weeks, which researchers consider encouraging for early-stage trials.
7. MariTide (Monthly Weight-Loss Injection)
MariTide is an experimental drug from Amgen.
Unique Feature
MariTide is designed for once-monthly dosing, which could make treatment much more convenient.
The drug works through a peptide-antibody fusion mechanism, aiming to deliver long-lasting metabolic effects.
It is currently in mid-stage clinical trials.
8. Amylin-Based Drugs (Petrelintide and Eloralintide)
Another category of next-generation therapies involves amylin analogues, which mimic a hormone involved in satiety and gastric emptying.
Recent trials of petrelintide have shown weight loss around 10.7% over 42 weeks, though results vary between studies.
These drugs may potentially offer fewer gastrointestinal side effects compared with traditional GLP-1 therapies.
The Future of Obesity and Metabolic Drugs
Experts believe the obesity-drug market could grow into a $100-billion-per-year industry, driving intense competition between pharmaceutical companies.
Future medications may involve:
- triple-hormone agonists
- combination therapies
- oral formulations
- long-acting monthly injections
- drugs targeting entirely new metabolic pathways
The next generation of therapies may also expand beyond weight loss to treat conditions such as:
- fatty liver disease (MASH)
- cardiovascular disease
- sleep apnea
- metabolic syndrome
Safety Considerations and Unknown Long-Term Effects
While these drugs show promise, researchers are still evaluating:
- long-term safety
- cardiovascular outcomes
- psychiatric effects
- gastrointestinal complications
- risk of rare adverse reactions
Many experts caution that rapid innovation may outpace long-term safety data, especially as these medications are used by millions of patients.
Next-generation GLP-1 and metabolic drugs represent one of the fastest-growing areas of pharmaceutical research. Experimental medications such as retatrutide, CagriSema, orforglipron, amycretin, survodutide, and VK2735 aim to produce greater weight loss, improved metabolic control, and more convenient dosing than current treatments.
However, most of these drugs are still undergoing clinical trials, and many questions remain about their long-term safety and effectiveness.
As research continues, these therapies could dramatically reshape how obesity, diabetes, and metabolic disease are treated in the coming decade.